Article Details

Syndax Pharmaceuticals: A Strong Buy on Robust Q2 Performance and Promising Market Strategy

Retrieved on: 2024-08-04 19:39:00

Tags for this article:

Click the tags to see associated articles and topics

Syndax Pharmaceuticals: A Strong Buy on Robust Q2 Performance and Promising Market Strategy. View article details on hiswai:

Excerpt

Jason Zemansky, an analyst from Bank of America Securities, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). ...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo